Table 1.
Granzyme B based human Cytolytic Fusion Proteins (hCFPs) resistant to serpin B9 inhibition, targeting surface proteins expressed in various cancers.
| Construct | Disease * | Target | Cell Line | P19 Expression in Cell Line | Cytotoxicity | Reference |
|---|---|---|---|---|---|---|
| GrB (wt)-H22(scFv) and GrBR201K-H22(scFv) | CMML | CD64+ | Cells from AMML and CMML patients. | Yes | Not specified | [35] |
| CD64+ HL60 | No | 4–7 nM | ||||
| GrB (wt)-ki4(scFv) and GrBR201K-Ki4(scFv) | cHL | CD30+ | L428 | Yes | [12] | |
| L540cy | No | |||||
| GrBR201K-scFv1711 | Epidermoid cancer cells | EGFR+ | A431 | Yes | 133.3 nM | [36] |
| RD target cells | Yes | 21.1 nM | ||||
| GrBR201K-αEpCAM(scFv) | TNBC | EpCAM+ | MDA-MB-231 | Yes | N/A | [37] |
| MDA-MB-468 | yes | 221 nM | ||||
| MDA-MB-453 | No | 307 nM |
* AMML, Acute myelomonocytic leukemia; CMML, Chronic myelomonocytic leukemia; cHL, Classical Hodgkin’s lymphoma; TNBC, Triple-negative breast cancer.